Christopher Plescia
Papers
1
Total Citations
12
H-Index
1
About
Christopher Plescia is a leading clinical investigator in head and neck oncology, with a focused expertise in human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) and novel immunotherapy strategies. His major contributions center on leveraging viral antigens to drive anti-tumor immunity, particularly through neoadjuvant approaches that aim to reduce treatment intensity without compromising cure. His landmark work, the TARGET-HPV trial, evaluates neoadjuvant HB-200—a first-in-class arenavirus-based immunotherapy targeting HPV16—combined with chemotherapy, followed by response-stratified de-intensification. This study represents a paradigm shift, exploring how viral-specific immunotherapy can enable personalized, less toxic treatment for HPV16+ OPC patients. With over 12 citations since its 2024 publication, this work has already garnered significant attention for its potential to redefine curative-intent therapy. Plescia’s research bridges immunology and clinical trial design, offering a roadmap for integrating biomarker-driven de-escalation into standard care. His achievements highlight a commitment to improving quality of life while maintaining excellent oncologic outcomes, making him a key voice in the evolving landscape of HPV-related cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1